ORPHAN Cures Act
Sponsored By: Senator Barrasso, John [R-WY]
Introduced
Summary
Expands exclusions for orphan drugs from Medicare's drug price negotiation calculations. This bill would change how the Medicare Drug Price Negotiation Program treats orphan drugs by excluding orphan-status time from market-approval clocks and by broadening which orphan drugs are exempt from negotiation.
Personalized for You
How does this bill affect your finances?
Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
1 provisions identified: 0 benefits, 1 costs, 0 mixed.
Delays price talks for orphan drugs
This bill would pause the Drug Price Negotiation Program clock for times a drug had orphan status. That pause would be left out of the program's timing rules. If enacted, some orphan-designated drugs could be kept off the negotiation list longer. Drug makers would face price talks later, and patients and insurers might see lower price relief delayed.
Sponsors & CoSponsors
Sponsor
Barrasso, John [R-WY]
WY • R
Cosponsors
Sen. Heinrich, Martin [D-NM]
NM • D
Sponsored 5/22/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.gov